{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-077804","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.225607+00:00","generated_at":"2026-06-26T22:04:35.270045+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Oncology reports Q4 2021 net loss of $34.4M; cash $430.9M through 2024","bullets":["Net loss $34.4M in Q4 2021 vs $18.4M in Q3 2021; FY 2021 net loss $67.5M vs $59.5M in FY 2020.","Cash and investments $430.9M as of Dec 31, 2021, expected to fund operations through 2024.","CLN-081 Phase 1/2a data: 39% confirmed PR at 100mg BID; median DOR >15 months, PFS 12 months.","CLN-081 received FDA Breakthrough Therapy Designation in Jan 2022; regulatory update expected Q1 2022.","CLN-049 and CLN-619 first-in-human dosing initiated Dec 2021; initial data expected by mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-077804","json":"https://secwatch.observer/filing/0001193125-22-077804.json","markdown":"https://secwatch.observer/filing/0001193125-22-077804.md","text":"https://secwatch.observer/filing/0001193125-22-077804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/0001193125-22-077804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312522077804/d331653d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:04:35.270045+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}